Fast Market Research announces the availability of the new Global Markets Direct report, "Breast Cancer - Pipeline Review, H2 2016", on their comprehensive research portal

Boston, MA -- (SBWire) -- 02/10/2017 --Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Breast Cancer - Pipeline Review, H2 2016, provides an overview of the Breast Cancer (Oncology) pipeline landscape.

Breast cancer is a cancer that develops from breast cells. Breast cancer usually starts off in the inner lining of milk ducts or the lobules that supply them with milk. Risk factors of breast cancer includes age, beginning of periods before the age of twelve or going through menopause after the age of fifty-five, being overweight, using hormone replacement therapy, consumption of birth control pills and consumption of alcohol. Symptoms include a lump in the breast, a change in size or shape of the breast or discharge from a nipple. Treatment includes radiation, lumpectomy, mastectomy, chemotherapy and hormone therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Breast Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Breast Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Get More Details on this Report and a Full Table of Contents at Breast Cancer - Pipeline Review, H2 2016

The Breast Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Breast Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 12, 45, 158, 167, 2, 13, 474, 96 and 9 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 16, 17, 1, 150 and 44 molecules, respectively.

Breast Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Report Scope

-The pipeline guide provides a snapshot of the global therapeutic landscape of Breast Cancer (Oncology).

-The pipeline guide reviews pipeline therapeutics for Breast Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

-The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

-The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

-The pipeline guide reviews key companies involved in Breast Cancer (Oncology) therapeutics and enlists all their major and minor projects.

-The pipeline guide evaluates Breast Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

-The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

-The pipeline guide reviews latest news related to pipeline therapeutics for Breast Cancer (Oncology)

Reasons to Get this Report

-Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

-Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

-Find and recognize significant and varied types of therapeutics under development for Breast Cancer (Oncology).

-Classify potential new clients or partners in the target demographic.

-Develop tactical initiatives by understanding the focus areas of leading companies.

-Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Companies Mentioned in this Report: 3-D Matrix Ltd, 3-V Biosciences Inc, 3SBio Inc, 4SC AG, A&G Pharmaceutical Inc, AB Science SA, AbbVie Inc, AbGenomics International Inc, Acceleron Pharma Inc, Acetylon Pharmaceuticals Inc, Adaptimmune Therapeutics Plc, ADC Therapeutics Sarl, Adgero Biopharmaceuticals Inc, Aduro BioTech Inc, Advanced Accelerator Applications SA, Advanced Cancer Therapeutics, Advanced Proteome Therapeutics Corp, Advantagene Inc, Advaxis Inc, Advenchen Laboratories LLC, Aegis Therapeutics LLC, Aeglea BioTherapeutics Inc, Aerpio Therapeutics Inc, Aeterna Zentaris Inc, Affichem SA, Agenus Inc, Agilvax Inc, Aileron Therapeutics Inc, Alchemia Ltd, Alethia Biotherapeutics Inc, Alissa Pharma, Almac Discovery Ltd, Alteogen Inc, Amarna Therapeutics BV, Ambrx Inc, American Gene Technologies International Inc, Amgen Inc, Ampio Pharmaceuticals Inc, Amplyx Pharmaceuticals Inc, Angion Biomedica Corp, ANP Technologies Inc, AntiCancer Inc, Antigen Express Inc, Antoxis Ltd, Aphios Corp, APIM Therapeutics AS, Aptevo Therapeutics Inc, Aravive Biologics Inc, ARMO Biosciences Inc, Armour Therapeutics Inc, Arno Therapeutics Inc, ArQule Inc, Arrien Pharmaceuticals LLC, Arvinas Inc, Asana BioSciences LLC, Ascentage Pharma Group Corp Ltd, AskAt Inc, Aslan Pharmaceuticals Pte Ltd, Astellas Pharma Inc, Astex Pharmaceuticals Inc, AstraZeneca Plc, Athenex Inc, ATLAB Pharma SAS, Atossa Genetics Inc, AVEO Pharmaceuticals Inc, Avexxin AS, Azaya Therapeutics Inc, Basilea Pharmaceutica Ltd, Batu Biologics Inc, Bavarian Nordic A/S, Bayer AG, BCN Biosciences LLC, BeiGene Ltd, Bellicum Pharmaceuticals Inc, Berg LLC, BerGenBio AS, Beta Pharma Inc, Bexion Pharmaceuticals LLC, BeyondSpring Pharmaceuticals Inc, Bicycle Therapeutics Ltd, Bio-Path Holdings Inc

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Drug Pipeline research reports at Fast Market Research

You may also be interested in these related reports:

-Metastatic Breast Cancer - Pipeline Review, H2 2016
-Cervical Cancer - Pipeline Review, H2 2016
-Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H2 2016
-Head And Neck Cancer - Pipeline Review, H2 2016
-Metastatic Breast Cancer - Pipeline Review, H1 2016